The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy-Reference-Cited by-同舟云学术

The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy

Published:2019-10 Issue: Volume:120 Page:86-96
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lee Siow Ming,Upadhyay Sunil,Lewanski Conrad,Falk Stephen,Skailes Geraldine,Woll Penella J.,Hatton Matthew,Lal Rohit,Jones Richard,Toy Elizabeth,Rudd Robin,Ngai Yenting,Edwards Alex,Hackshaw Allan

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial;Lee;Lancet Oncol,2012

2. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

3. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and Erlotinib Lung Cancer Trial (DELTA);Kawaguchi;J Clin Oncol,2014

4. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial;Garassino;Lancet Oncol,2013

5. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future;Chan;Transl Lung Cancer Res,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-11

2. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis;Clinical Medicine Insights: Oncology;2023-01

3. Molecular & Translational Biology of the Blood-Based VeriStrat® Proteomic Test Used in Cancer Immunotherapy Treatment Guidance;2022-12-30

4. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study;Cancer Immunology, Immunotherapy;2020-11-24

5. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis;Current Medical Research and Opinion;2020-07-23